Search results
Results From The WOW.Com Content Network
October 18, 2024. 0. Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorization for Eltrombopag Viatris (eltrombopag), a generic medicine ...
July 02, 2015. 0. Some mutations in patients with aplastic anemia influence the response to therapy and long-term disease outcomes, according to a genomic cohort study by Tetsuichi Yoshizato, MD ...
Severe aplastic anemia is a rare but devastating disease with a high incidence of morbidity and mortality. This paper is of major importance as it revolutionizes severe aplastic anemia therapy and ...
The virus can cause fetal anemia, which will need to be monitored closely. Fetal loss or a miscarriage is a rare outcome that occurs in less than 10% of those with acute infection during pregnancy ...
Given the prevalence and consequences of anemia in this population, the National Comprehensive Cancer Network (NCCN) recommends routine follow-up evaluations for patients with hemoglobin levels ...
Immunomodulatory pathways of antimicrobial agents. (1) Modulation of genes involved in immune reactions, or of the neurohormonal system which regulates immune functions. (2) Toxic or immunotoxic ...
August 26, 2014. 0. The US Food and Drug Administration (FDA) has approved a supplemental new drug application for eltrombopag (Promacta, GlaxoSmithKline) for use in patients with severe aplastic ...
We call the interaction between chronic renal failure, CHF and anemia the cardiorenal anemia syndrome. Each of these three elements causes or exacerbates the others, and their correction can ...
Table of Contents. From International journal of clinical pharmacology and therapeutics. 2023 - 61 (12) Potential drug-drug interactions in a multi-center study of death cases of COVID-19: The ...
Results: Anemia was diagnosed in 13 patients (hemoglobin levels < 13.5 mg/dL in male patients and < 12.0 mg/dL in female patients), which represents a prevalence of 13%. Anemic COPD patients ...